.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A systematic review and meta-analysis examined whether blood eosinophil count can help predict the effect of inhaled corticosteroids on exacerbation risk in COPD. The investigators synthesized randomized and observational evidence using commonly studied eosinophil thresholds. Across randomized trial data, higher blood eosinophil counts were associated with a greater likelihood of exacerbation reduction with ICS-containing treatment, while the observational evidence was more heterogeneous. The practical implication is that eosinophil count can support, but should not replace, clinical decision-making. It is particularly useful when deciding whether to introduce, continue, or withdraw an ICS in a patient whose exacerbation history, smoking status, pneumonia risk, and possible asthma overlap are already being considered. The analysis also supports the broader shift away from treating COPD as a single spirometric phenotype. Blood eosinophils are a low-burden biomarker that can add information when the treatment decision is uncertain. For clinicians attending a conference session on phenotyping and ICS decisions, the paper offers a useful evidence base for using biomarkers as part of a structured assessment rather than as a stand-alone prescription trigger.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systematic review and meta-analysis examined whether blood eosinophil count can help predict the effect of inhaled corticosteroids on exacerbation risk in COPD. The investigators synthesized randomized and observational evidence using commonly studied eosinophil thresholds. Across randomized trial data, higher blood eosinophil counts were associated with a greater likelihood of exacerbation reduction with ICS-containing treatment, while the observational evidence was more heterogeneous. The practical implication is that eosinophil count can support, but should not replace, clinical decision-making. It is particularly useful when deciding whether to introduce, continue, or withdraw an ICS in a patient whose exacerbation history, smoking status, pneumonia risk, and possible asthma overlap are already being considered. The analysis also supports the broader shift away from treating COPD as a single spirometric phenotype. Blood eosinophils are a low-burden biomarker that can add information when the treatment decision is uncertain. For clinicians attending a conference session on phenotyping and ICS decisions, the paper offers a useful evidence base for using biomarkers as part of a structured assessment rather than as a stand-alone prescription trigger.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
